WellDyneRx Response to Recent PBM News Coverage
On a recent episode of 60 Minutes, Lesley Stahl did a segment called “The Rockford File” where she investigated a pending class-action lawsuit brought by the city of Rockford, Illinois against pharmaceutical manufacturer Mallinckrodt and their pharmacy benefit manager (PBM). The case involves a drug called HP Acthar that originally sold for $40 a vial in 2001, but today is sold for more than $40,000.
Knowing about this and other similar medications that have experienced significant price hikes in recent years, WellDyneRx launched the WellManaged – Hyperinflationary Drugs program. This program monitors the pricing and clinical relevance of new and existing medications. Drugs are added to an exclusion list if they are significantly more costly than medications offering similar clinical outcomes.
To date, WellDyneRx has identified 243 medications which are part of the Hyperinflationary Drugs program. Unfortunately, many of our clients have not implemented this program and are at risk of paying too much for medications that WellDyneRx deems “wasteful” because there are less expensive, clinicallyequivalent options available.
2018 Quarter Two WellInformed Table Contents